2-萘甲酰胺,N-(3-硝基苯基)- | 176033-63-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 中文名称: 2-萘甲酰胺,N-(3-硝基苯基)-
• 英文名称: N-(3-nitrophenyl)-2-naphthamide
• 英文别名: N-(3-nitrophenyl)-2-naphthalenecarboxamide；N-(3-nitrophenyl)naphthalene-2-carboxamide
• CAS: 176033-63-9
• 化学式: C₁₇H₁₂N₂O₃
• 分子量: 292.294
• InChiKey: RYVPBMJIUCQSLK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  22
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  74.9
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-萘甲酰胺,N-(3-硝基苯基)- 在 palladium 10% on activated carbon 、 甲酸铵 、 copper(l) chloride 、 sodium hydroxide 作用下， 以 异丙醇 、 丙酮 、 乙腈 为溶剂， 120.0 ℃ 、344.75 kPa 条件下， 反应 1.1h， 生成 N-(3-((3,4,5-trimethoxybenzoylamino)carbonylamino)phenyl)-2-naphthamide
  参考文献：
  名称：

  Acylthiourea, Acylurea, and Acylguanidine Derivatives with Potent Hedgehog Inhibiting Activity

  摘要：

  The Smoothened (Smo) receptor is the major transducer of the Hedgehog (Hh) signaling pathway. On the basis of the structure of the acylthiourea Smo antagonist (MRT-10), a number of different series of analogous compounds were prepared by ligand-based structural optimization. The acylthioureas, originally identified as actives, were converted into the corresponding acylureas or acylguanidines. In each series, similar structural trends delivered potent compounds with IC50 values in the nanomolar range with respect to the inhibition of the Hh signaling pathway in various cell-based assays and of BODIPY-cyclopamine binding to human Smo. The similarity of their biological activities, in spite of discrete structural differences, may reveal the existence of hydrogen-bonding interactions between the ligands and the receptor pocket. Biological potency of compounds 61, 72, and 86 (MRT-83) were comparable to those of the clinical candidate GDC-0449. These findings suggest that these original molecules will help delineate Smo and Hh functions and can be developed as potential anticancer agents.

  DOI：

  10.1021/jm2013369
• 作为产物：
  描述：

  2-萘甲酸 在 草酰氯 、 三乙胺 、 N,N-二甲基甲酰胺 作用下， 以 甲苯 为溶剂， 反应 48.0h， 生成 2-萘甲酰胺,N-(3-硝基苯基)-
  参考文献：
  名称：

  Investigating the Spectrum of Biological Activity of Substituted Quinoline-2-Carboxamides and Their Isosteres

  摘要：

  本研究制备并鉴定了一系列 35 种取代的喹啉-2-羧酰胺和 33 种取代的萘-2-羧酰胺。对它们抑制菠菜叶绿体光合电子传递（PET）的活性进行了测试。还对合成的化合物进行了针对四种霉菌的体外初筛。N-环庚基喹啉-2-甲酰胺、N-环己基喹啉-2-甲酰胺和 N-(2-苯基乙基)喹啉-2-甲酰胺对结核杆菌的活性高于标准异烟肼。与标准异烟肼或吡嗪酰胺相比，N-环己基喹啉-2-甲酰胺和 N-(2-苯基乙基)喹啉-2-甲酰胺对结核杆菌的活性更高；与标准异烟肼或吡嗪酰胺相比，2-(吡咯烷-1-羰基)喹啉和 1-(2-萘甲酰基)吡咯烷对堪萨斯疫霉菌和副结核杆菌的活性更高。最有效的抗霉菌化合物对人类单核细胞白血病 THP-1 细胞系的毒性很小。最有效化合物 N-苄基-2-萘甲酰胺的 PET 抑制活性（以 IC50 值表示）为 7.5 μmol/L。本文讨论了所有化合物的结构-活性关系。

  DOI：

  10.3390/molecules17010613

文献信息

• Heterobicyclic derivatives
  申请人：FUJISAWA PHARMACEUTICAL CO., LTD.

  公开号：US20020107251A1

  公开（公告）日：2002-08-08

  Heterobicyclic derivatives of the formula: 1 wherein R 1 is aryl which may have suitable substituent(s), ar(lower)alkyl which may have suitable substituent(s), halo(lower)alkyl, protected carboxy(lower)alkyl, acyl(lower)alkyl, heterocyclic group or heterocyclic(lower)alkyl which may have suitable substituent(s), R 2 is aryl which may have suitable substituent(s) or heterocyclic group, and R 3 is hydrogen, lower alkoxy or arylthio, and a pharmaceutically acceptable salt thereof which are useful as a medicament.

  公式为1的杂环双环衍生物，其中：R1是苯基，可以具有适当的取代基；芳基（较低）烷基，可以具有适当的取代基；卤代（较低）烷基；保护的羧基（较低）烷基；酰基（较低）烷基；杂环基或者可以具有适当的取代基的杂环（较低）烷基；R2是苯基，可以具有适当的取代基或者杂环基；R3是氢、较低烷氧基或者芳基硫醚。它们的药物可接受盐是有用的。
• Pyrido[2,3-a]pyrazine derivatives as PDE-IV and TNF inhibitors
  申请人：FUJISAWA PHARMACEUTICAL CO., LTD.

  公开号：EP0920867A1

  公开（公告）日：1999-06-09

  Heterobicyclic derivatives of formula (I) wherein R1 is aryl which may have suitable substituent(s), ar(lower)alkyl which may have suitable substituent(s), halo(lower)alkyl, protected carboxy(lower)alkyl, acyl(lower)alkyl, heterocyclic group or heterocyclic(lower)alkyl which may have suitable substituent(s), R2 is aryl which may have suitable substituent(s) or heterocyclic group, and R3 is hydrogen, lower alkoxy or arylthio, and a pharmaceutically acceptable salt thereof which are useful as PDE IV and TNF inhibitors for the treatment of hepatitis in human beings and animals.

  式(I)的杂双环衍生物 其中 R1 是芳基，可具有合适的取代基；ar(低级)烷基，可具有合适的取代基；卤代(低级)烷基；受保护的羧基(低级)烷基；酰基(低级)烷基；杂环基团或杂环(低级)烷基，可具有合适的取代基、R2 是芳基（可有适当的取代基）或杂环基，R3 是氢、低级烷氧基或芳硫基，及其药学上可接受的盐，可作为 PDE IV 和 TNF 抑制剂用于治疗人类和动物的肝炎。
• HETEROBICYCLIC DERIVATIVES
  申请人：FUJISAWA PHARMACEUTICAL CO., LTD.

  公开号：EP0770079B1

  公开（公告）日：2003-02-12
• US6426345B1
  申请人：——

  公开号：US6426345B1

  公开（公告）日：2002-07-30
• US6727245B2
  申请人：——

  公开号：US6727245B2

  公开（公告）日：2004-04-27